만성 림프성 백혈병 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 유형별, 치료법별, 투여 경로별, 최종사용자별, 지역별 및 경쟁별 세분화(2020-2030년)
Chronic Lymphocytic Leukemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Route of Administration, By End user, By Region and Competition, 2020-2030F
상품코드:1886352
리서치사:TechSci Research
발행일:2025년 12월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 만성 림프성 백혈병 치료 시장은 2024년 133억 7,000만 달러에서 2030년까지 215억 1,000만 달러로, CAGR 8.25%로 성장할 것으로 예측됩니다. 세계 만성 림프구성 백혈병(CLL) 치료제 시장은 혈액과 골수에서 비정상적인 림프구 증식을 특징으로 하는 이 특정 암의 진행을 관리하고 완화하기 위해 고안된 다양한 치료적 개입을 포괄합니다. 시장 확대를 지원하는 주요 촉진요인으로는 전 세계에서 CLL 발생률 증가, 특히 고령화 인구에서 CLL 발생률 증가, 환자 치료 결과를 개선하는 표적치료제 및 면역치료제의 지속적인 발전 등이 있습니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
133억 7,000만 달러
시장 규모 : 2030년
215억 1,000만 달러
CAGR : 2025-2030년
8.25%
가장 빠르게 성장하는 부문
공격성 만성 림프성 백혈병(CLL)
최대 시장
북미
주요 시장 성장 촉진요인
세계 만성 림프구성 백혈병 치료제 시장은 표적치료제와 정밀의료의 지속적인 발전으로 인해 큰 영향을 받고 있습니다. 이러한 혁신은 암 성장에 관여하는 특정 분자 경로에 초점을 맞추고 있으며, 기존 화학요법에 비해 더 효과적이고 독성이 낮은 대안을 제공합니다.
주요 시장 과제
새로운 만성 림프구성 백혈병 치료제에 따른 막대한 비용이 시장 확대에 큰 걸림돌로 작용하고 있습니다. 이러한 고비용은 특히 의료 예산이 부족한 개발도상국에서 환자들이 첨단 치료를 받을 수 있는 기회를 제한하고 있습니다.
주요 시장 동향
새로운 병용요법에 대한 전략적 초점이 치료 저항성에 대한 대응과 효과 향상으로 이어지면서 전 세계 만성 림프구성 백혈병 치료제 시장에 큰 영향을 미치고 있습니다. 이 접근법은 브루톤형 티로신 키나아제 억제제와 BCL-2 억제제 등 서로 다른 작용기전을 가진 약물을 결합하여 보다 깊고 지속적인 환자 반응을 달성하는 것을 목표로 하고 있습니다.
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 만성 림프성 백혈병 치료 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
유형별(공격성 CLL, 비공격성 CLL, 기타)
치료법별(표적 약물 요법, 화학요법, 골수 이식, 면역치료)
투여 경로별(경구, 정맥내, 기타)
최종사용자별(병원, 진단 검사실, 연구기관, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의 만성 림프성 백혈병 치료 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 만성 림프성 백혈병 치료 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 만성 림프성 백혈병 치료 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 만성 림프성 백혈병 치료 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 만성 림프성 백혈병 치료 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
합병·인수
제품 출시
최근 동향
제13장 세계의 만성 림프성 백혈병 치료 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
AbbVie, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca PLC
Johnson and Johnson Services, Inc.
Genentech, Inc.
Genmab A/S
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
GlaxoSmithKline plc
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Chronic Lymphocytic Leukemia Treatment Market will grow from USD 13.37 Billion in 2024 to USD 21.51 Billion by 2030 at a 8.25% CAGR. The global chronic lymphocytic leukemia (CLL) treatment market encompasses various therapeutic interventions designed to manage and mitigate the progression of this specific type of cancer, characterized by the proliferation of abnormal lymphocytes in the blood and bone marrow. Key drivers bolstering market expansion include the rising global incidence of CLL, particularly among the aging population, and continuous advancements in targeted therapies and immunotherapies offering improved patient outcomes.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 13.37 Billion
Market Size 2030
USD 21.51 Billion
CAGR 2025-2030
8.25%
Fastest Growing Segment
Aggressive CLL
Largest Market
North America
Key Market Drivers
The global Chronic Lymphocytic Leukemia treatment market is significantly influenced by continued advancements in targeted therapies and precision medicine. These innovations focus on specific molecular pathways involved in cancer growth, offering more effective and often less toxic alternatives to traditional chemotherapy. The development of Bruton's tyrosine kinase BTK and BCL2 inhibitors has particularly transformed treatment paradigms, enabling improved patient outcomes and expanded therapeutic options for various disease stages, including refractory cases.
Key Market Challenges
The substantial cost associated with novel chronic lymphocytic leukemia treatment modalities presents a significant challenge to market expansion. These elevated expenses limit patient access to advanced therapies, particularly in developing economies where healthcare budgets are frequently constrained. The financial burden can lead to delayed treatment initiation or even non-adherence, directly impacting therapeutic outcomes and the overall market penetration of innovative drugs.
Key Market Trends
The strategic focus on novel combination therapies is significantly influencing the global Chronic Lymphocytic Leukemia treatment market by offering enhanced efficacy and addressing treatment resistance. This approach involves combining agents with different mechanisms of action, such as Bruton's tyrosine kinase inhibitors with BCL-2 inhibitors, to achieve deeper and more durable patient responses.
Key Market Players
AbbVie, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca PLC
Johnson and Johnson Services, Inc.
Genentech, Inc.
Genmab A/S
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
GlaxoSmithKline plc
Report Scope:
In this report, the Global Chronic Lymphocytic Leukemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Chronic Lymphocytic Leukemia Treatment Market, By Type:
Aggressive CLL
Indolent CLL
Others
Chronic Lymphocytic Leukemia Treatment Market, By Treatment:
Targeted Drug Therapy
Chemotherapy
Bone Marrow Transplant
Immunotherapy
Chronic Lymphocytic Leukemia Treatment Market, By Route of Administration:
Oral
Parental
Others
Chronic Lymphocytic Leukemia Treatment Market, By End user:
Hospital
Diagnostic Laboratories
Research Institutes
Others
Chronic Lymphocytic Leukemia Treatment Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Chronic Lymphocytic Leukemia Treatment Market.
Available Customizations:
Global Chronic Lymphocytic Leukemia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Chronic Lymphocytic Leukemia Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Aggressive CLL, Indolent CLL, Others)
5.2.2. By Treatment (Targeted Drug Therapy, Chemotherapy, Bone Marrow Transplant, Immunotherapy)
5.2.3. By Route of Administration (Oral, Parental, Others)
5.2.4. By End user (Hospital, Diagnostic Laboratories, Research Institutes, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Chronic Lymphocytic Leukemia Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Treatment
6.2.3. By Route of Administration
6.2.4. By End user
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Chronic Lymphocytic Leukemia Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Treatment
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By End user
6.3.2. Canada Chronic Lymphocytic Leukemia Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Treatment
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By End user
6.3.3. Mexico Chronic Lymphocytic Leukemia Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Treatment
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By End user
7. Europe Chronic Lymphocytic Leukemia Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Treatment
7.2.3. By Route of Administration
7.2.4. By End user
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Chronic Lymphocytic Leukemia Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Treatment
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By End user
7.3.2. France Chronic Lymphocytic Leukemia Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Treatment
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By End user
7.3.3. United Kingdom Chronic Lymphocytic Leukemia Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Treatment
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By End user
7.3.4. Italy Chronic Lymphocytic Leukemia Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Treatment
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By End user
7.3.5. Spain Chronic Lymphocytic Leukemia Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Treatment
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By End user
8. Asia Pacific Chronic Lymphocytic Leukemia Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Treatment
8.2.3. By Route of Administration
8.2.4. By End user
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Chronic Lymphocytic Leukemia Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Treatment
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By End user
8.3.2. India Chronic Lymphocytic Leukemia Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Treatment
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By End user
8.3.3. Japan Chronic Lymphocytic Leukemia Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Treatment
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By End user
8.3.4. South Korea Chronic Lymphocytic Leukemia Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Treatment
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By End user
8.3.5. Australia Chronic Lymphocytic Leukemia Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Treatment
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By End user
9. Middle East & Africa Chronic Lymphocytic Leukemia Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Treatment
9.2.3. By Route of Administration
9.2.4. By End user
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Chronic Lymphocytic Leukemia Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Treatment
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By End user
9.3.2. UAE Chronic Lymphocytic Leukemia Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Treatment
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By End user
9.3.3. South Africa Chronic Lymphocytic Leukemia Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Treatment
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By End user
10. South America Chronic Lymphocytic Leukemia Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Treatment
10.2.3. By Route of Administration
10.2.4. By End user
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Chronic Lymphocytic Leukemia Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Treatment
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By End user
10.3.2. Colombia Chronic Lymphocytic Leukemia Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Treatment
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By End user
10.3.3. Argentina Chronic Lymphocytic Leukemia Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Treatment
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By End user
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Chronic Lymphocytic Leukemia Treatment Market: SWOT Analysis
